J&J’s shrinking infectious disease and vaccine plans leave partners in limbo

2023-07-21
疫苗临床2期
Cidara and Arrowhead each await news on partnered assets with Janssen after the Big Pharma significantly shrunk its infectious disease footprint.
Cidaran & JArrowheady be steadfast in its decision to divest fJanssen development of vaccines and infectious disease meds but the Big Pharma's partners in this therapeutic area have been left in limbo.
Johnson & Johnsoncs said late Thursday that while it's aware of J&J's reprioritization, it has yet to hear whether or not a two-year-old partnership has been axed. The two companies had collaborated on CD388, a prophylactic for influenza A and B. In a post-market release, the biotech said that “at this time” Janssen has made no indication that it plans to terminate the program.
Cidara Therapeuticsists the antiviral, also known as JNJ-0953, oJ&Jts pipeline, however.influenzaJanssen
Janssenless, Cidara says it will continue to work witJNJ-0953g Pharma on three ongoing clinical trials testing CD388. Two of those trials, each in phase 1, wrapped up recruitment in May and are each listed as active on the clinical trial record. A phase 2a trial is also still listed as active after completing recruitment in late March.
Once the biotCidarabmits the phase 2a data to Janssen, the larger company will have 90 days to decide whether or not to advance the program forward. If Janssen does in fact decide to proceed, it will have sole responsibility for either future development or business development efforts to secure a third party.
In yesterday's release, Cidara CEO Jeffrey SteJanssen his team remains confident in the potential of CD388, “whether we or another party further advanceJanssenpromising asset.”
Arrowhead PharmaceuticalCidarafound itself in a similar position ever since Janssen relayed to the biotech earlier this year that a $3.7 billion collaboration signed in 2018 was no more. That deal centered on hepatitis B med JNJ-3989, a disease area that’s been completely wiped out amid J&J’s shakeup.
Arrowhead Pharmaceuticalsg to find out whether J&J, which has the rights to Janssenet, will out-license to another company or hand it back to the biotech. A separate nonalcoholic steatohepatitis (NASH) candidahepatitis Bse frJNJ-3989eal has already been given back.J&J
Arrowheaderson for Arrowhead told Fierce BiotecJ&Jhursday that the company has no further update to provide.nonalcoholic steatohepatitis (NASH)
The positions both Arrowheadd Arrowhead find themselves in stem from Janssen's move away from infectious disease and vaccine development. An updated clinical pipeline posted by Janssen yesterday showed that the company halved the number of assets in this therapeutic area compared to the first quarter of the year. Team members were first notified about plans to shrink the unit back in late January.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路,让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。